Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

VenatoRx Pharmaceuticals

  • Tony Meehan, VenatoRx Pharmaceuticals

VenatoRx is a private pharmaceutical company that is focused on the discovery and development of novel anti-infectives to treat multi-drug-resistant (MDR) bacterial infections and hard-to-treat viral infections. VenatoRx’s lead product, VNRX-5133, is an injectable broad-spectrum beta-lactamase inhibitor (BLI) that directly inhibits all four Ambler classes of beta-lactamases. In addition, VenatoRx has a broad pipeline of preclinical programs, including a broad-spectrum orally bioavailable BLI, a novel class of Penicillin-Binding Protein (PBP) inhibitors that are impervious to beta-lactamase-driven resistance, and novel antiviral agents.

  • Date:Monday, February 11
  • Time:3:30 PM - 3:45 PM
  • Room:Gramercy
  • Location:7th Floor
  • Session Type:Company Presentation
  • Submission ID:23524
  • Company Presentation - Presentation Type:Privately Funded Company
  • Goal for Presentation:Company Update and Investor Awareness
  • Company Website:www.venatorx.com
  • Company HQ City:Malvern
  • Company HQ State:Pennsylvania
  • Company HQ Country:United States
  • Total Amount Raised to Date, in All Rounds:$50 Million
  • Size of Last Investment Round:$47 Million
  • Previous and Current Investors:Versant Ventures, Abingworth, Foresite Capital, Everest Medicines
  • CEO/Top Company Official:Christopher Burns, Ph.D., CEO & President
  • Year Founded:2010
  • Main Therapeutic Focus:Infectious Diseases
  • Lead Product in Development:Cefepime/VNRX-5133
  • Development Phase of Primary Product:Phase III
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):3
Speakers
Tony Meehan
VenatoRx Pharmaceuticals
Back